Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS??? EQUITY (DEFICIT)

v3.22.4
STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common stocks
Treasury stocks
Additional paid-in capital
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2019 73,690,340        
Beginning balance at Dec. 31, 2019 $ 79,700        
Increase (Decrease) in Temporary Equity [Roll Forward]          
Accretion of preferred stocks to redemption value $ 7,297        
Ending balance (in shares) at Dec. 31, 2020 73,690,340        
Ending balance at Dec. 31, 2020 $ 86,997        
Beginning balance (in shares) at Dec. 31, 2019   15,969,260      
Balance at Dec. 31, 2019 (42,787) $ 2 $ (1,629) $ 3,058 $ (44,218)
Beginning balance (in shares) at Dec. 31, 2019     1,914,328    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of preferred stocks to redemption value (7,297)     (4,214) (3,083)
Capital contribution 504     504  
Stock-based compensation 584     584  
Stock options exercised (in shares)   306,349      
Stock options exercised 78     78  
Net loss (812)       (812)
Ending balance (in shares) at Dec. 31, 2020   16,275,609      
Balance at Dec. 31, 2020 (49,730) $ 2 $ (1,629) 10 (48,113)
Ending balance (in shares) at Dec. 31, 2020     1,914,328    
Increase (Decrease) in Temporary Equity [Roll Forward]          
Accretion of preferred stocks to redemption value $ 77,063        
Conversion of redeemable convertible preferred stock into common stock (in shares) (73,690,340)        
Conversion of redeemable convertible preferred stock into common stock $ (164,060)        
Ending balance (in shares) at Dec. 31, 2021 0        
Ending balance at Dec. 31, 2021 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of preferred stocks to redemption value (77,063)     (4,172) (72,891)
Conversion of redeemable convertible preferred stock into common stock (in shares)   73,690,340      
Conversion of redeemable convertible preferred stock into common stock 164,060 $ 7   164,053  
Reverse recapitalization, net (in shares)   25,154,340 (1,914,328)    
Reverse recapitalization, net 126,026 $ 3 $ 1,629 124,394  
Conversion of Legacy Innovid warrants ( in shares)   507,994      
Conversion of Legacy Innovid Warrants 5,080     5,080  
Warrant exercised (in shares) [1]   132,392      
Stock-based compensation 3,273     3,273  
Stock options exercised (in shares)   3,256,705      
Stock options exercised 1,081     1,081  
Net loss $ (11,472)       (11,472)
Ending balance (in shares) at Dec. 31, 2021 119,017,380 119,017,380      
Balance at Dec. 31, 2021 $ 161,255 $ 12 $ 0 293,719 (132,476)
Ending balance (in shares) at Dec. 31, 2021     0    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock, shares issued (in shares) 119,017,380        
Ending balance (in shares) at Dec. 31, 2022 0        
Ending balance at Dec. 31, 2022 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock Issued During Period, Shares, Acquisitions (in shares)   11,549,465      
Common stock and equity awards issued for acquisition of TVS 47,152 $ 1   47,151  
Stock-based compensation 14,945     14,945  
Stock options exercised and RSUs vested (in shares)   3,315,569      
Stock options exercised and RSUs vested 986     986  
Net loss $ (18,410)       (18,410)
Ending balance (in shares) at Dec. 31, 2022 133,882,414        
Balance at Dec. 31, 2022 $ 205,928 $ 13 $ 0 $ 356,801 $ (150,886)
Ending balance (in shares) at Dec. 31, 2022     0    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock, shares issued (in shares) 133,882,414        
[1] The warrant was exercised in November 2021 and was net share settled.